Example: marketing

BRIDION® Intravenous 200mg, 500mg

2015 10 7 2014 8 873929 22200 AMX002280002010 4 2008 7 22200 AMX002290002010 4 2008 7 200mg500mg 1 P0508-B2 3 BRIDION Intravenous 200mg, 500mg 1. 1 200mg 2mL 200mgpH 500mg 5mL 500mg2. pH 7 8 1 2 TOF 2 T2 1 2mg/kg PTC 1 2 1-2 PTC 1 4mg/kg 3 1 16mg/kg 1. 2mg/kg 4mg/kg 2.

2015年10月改訂(第7版) 2014年8月改訂 873929 日本標準商品分類番号 承認番号 薬価収載 販売開始 国際誕生 22200amx00228000

Tags:

  500mg

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of BRIDION® Intravenous 200mg, 500mg

1 2015 10 7 2014 8 873929 22200 AMX002280002010 4 2008 7 22200 AMX002290002010 4 2008 7 200mg500mg 1 P0508-B2 3 BRIDION Intravenous 200mg, 500mg 1. 1 200mg 2mL 200mgpH 500mg 5mL 500mg2. pH 7 8 1 2 TOF 2 T2 1 2mg/kg PTC 1 2 1-2 PTC 1 4mg/kg 3 1 16mg/kg 1. 2mg/kg 4mg/kg 2.

2 1. 1 2 3 4 5 6 7 8 9 1 2. 1 2 16mg/kg 3 4 5 2010 4 2010 4 2 6 7 2 3 3.

3 4. 2 16mg/kg 1,477 99 1,378 175 38 19 1 1 2 3 4 16mg/kg 14/148 4mg/kg 10/151 2 1 5% 1% -N- - - 2- 5. 6. 1 2 4 7.

4 5 8. 6 9. 1. 7 mg/kg AUC0- g min/mL CL mL/min Vss mL t1/2 min 114561 106 12,071 107 8144,604 103 11,799 132 16149,670 11,370 143 CV 6 4mg/kg APTT PT 2.

5 8 6 14C- 4mg/kg 90% 24 3. 30mL/min 80mL/min 2mg/kg 9 30mL/min 30 50mL/min 80mL/min 4mg/kg mg/kg AUC0- g min/mL CL mL/min Vss mL t1/2 min 2 131,728 13,800 139 *1327,463 114 108 15,986 2,139 121 4 63,750 14,149 149 69,058 15,9 38 21 .9 344 620,312 15, 071 794 CV : 9 high-flux 6 70% low-flux 4. 10 11 0 125 M 0 250 M in vitro 1. II 12 15 ASA Class1 3 TOF 2 T2 PTC 1 2 1-2 PTC TOF T4/T1 TOF T4/T1 PPS T2 n=7 n=9 n=6 n=7 1-2 PTC n=11 n=10 n=10 n=8 2.

6 III 16 17 1 ASA Class1 4 TOF 2 T2 3 50 g/kg PTC 1 2 1-2 PTC 70 g/kg TOF T4/T1 p< TOF T4/T1 * ITT T2 1-2 PTC n=48 n=48 n=48 n=36 n=45 n=37 n=37 n=47 : 2 ASA Class1 2 3 T1 10% n=55 T1 10% n=55 p< 3. 18 ASA Class1 3 TOF T2 TOF T4/T1 18 64 n=48 65 74 n=62 75 n=40 4.

7 19 20 30mL/min 80mL/min TOF T2 PTC 1 2 1-2 PTC TOF T4/T1 TOF T4/T1 T2 ASA Class1 2 n=14 PP ASA Class2 3 n=15 PP 1-2 PTC ASA Class1 3 n=32 ITT ASA Class2 3 n=35 ITT 4 1. 106M-1 21 2. In vitro 22 3. TOF T1 90% 460nmol/kg TOF T4/T1 TOF T4/T1 n=4 n=4 23 4.

8 ED90 90% 5 800nmol/kg 70nmol/kg 1,150nmol/kg n=4 TOF T4/T1 TOF T4/T1 24 Sugammadex Sodium Cyclooctakis- 1 4 -{6-S-[2-(sodium carboxylato)ethyl]- 6-thio- -D-glucopyranosyl} C72H104O48S8Na8 200mg 2mL 10 500mg 5mL 10 1 2 3 4 5 Plaud B, et al.: Anesthesiology 2009, 110, 2846 7 8 Peeters P, et al.: Biopharm Drug Dispos 2011, 32, 1599 Staals LM, et al.

9 : Br J Anaesth 2010, 104, 3110 11 12 T2 1 3 P hringer FK, et al.: Br J Anaesth 2010, 105, 61014 1 - 2 PTC 15 Duvaldestin P, et al.: Anesth Analg 2010, 110, 74 16 Jones RK, et al.: Anesthesiology 2008, 109, 816 17 Lee C, et al.: Anesthesiology 2009, 110, 1020 1 8 McDonagh DL, et al.: Anesthesiology 2011, 114, 3181 9 Staals LM, et al.: Br J Anaesth 2008, 101, 4922 0 Panhuizen IF, et al.: Br J Anaesth 2015, 114, 77721 22 Zhang MQ, et al.: Drugs Fut 2003, 28, 34723 Egmond J, et al.: Eur J Anaesthesiol 2001, 18 Suppl23 , 10024 1 -13-12 0120-024-961


Related search queries